The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs
@article{Klotz2007TheRO, title={The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs}, author={Ulrich Klotz}, journal={Clinical Pharmacokinetics}, year={2007}, volume={46}, pages={271-279} }
Several different factors, including pharmacogenetics, contribute to inter-individual variability in drug response. Like most other agents, many antiepileptic drugs (AEDs) are metabolised by a variety of enzymatic reactions, and the cytochrome P450 (CYP) superfamily has attracted considerable attention. Some of those CYPs exist in the form of genetic (allelic) variants, which may also affect the plasma concentrations or drug exposure (area under the plasma concentration-time curve [AUC]) of…
146 Citations
[Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450].
- Biology, MedicineRevista de neurologia
- 2013
The identification of interindividual variability in the response to AEDs may allow the personalized treatment with the aim of maximize the efficiency and minimize risk, regardless of the clinical variability and adverse effects could be manifest in a minority of the patients.
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
- Biology, MedicinePharmaceuticals
- 2010
The state of research on the effects of mutations of drug-metabolizing enzymes on the pharmacokinetics and pharmacodynamics of AED therapies is summarized and future directions for the dose-adjustment of A ED are discussed.
Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs
- Psychology, BiologyExpert opinion on drug metabolism & toxicology
- 2014
This review summarizes the pharmacogenetics (PGx) of AEDs and provides a model-based approach that enables the integration of PGx data with other relevant sources of variability, such as demographic characteristics and co-medications.
The clinical impact of cytochrome P450 polymorphisms on anti-epileptic drug therapy
- Biology, Medicine
- 2010
It is reported that the CYP2C19-deficient genotype is associated with the serum concentration of an active metabolite of clobazam, N-desmethylclobazem, and with the clinical efficacy of clOBazam therapy.
Farmacogenética e antiepilépticos (farmacologia das drogas antiepilépticas: da teoria à prática)
- Biology, Psychology
- 2008
The optimized use of antiepileptic drugs to treatment of epilepsy is usually compromised by lack of therapeutic response, unexpected side effects and unexplained variations of antIEpileptics plasma levels, which could explain some of these problems.
The clinical impact of pharmacogenetics on the treatment of epilepsy
- Biology, MedicineEpilepsia
- 2009
This article reviews the published work with particular emphasis on pharmacogenetic alterations that may affect efficacy, tolerability, and safety of antiepileptic drugs (AEDs), including variation in genes encoding drug target, drug transport, drug metabolizing, and human leucocyte antigen (HLA) proteins.
The effect of polymorphic metabolism enzymes on serum phenytoin level
- Biology, MedicineNeurological Sciences
- 2014
The mean serum concentration of phenytoin of the polymorphic patients with epilepsy was higher than that for the wild-type alleles both in the monotherapy and polytherapy patients.
The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children
- Biology, MedicineSeizure
- 2016
CYP3A5∗3 and C3435T MDR1 Polymorphisms in Prognostication of Drug-Resistant Epilepsy in Children and Adolescents
- Biology, MedicineBioMed research international
- 2013
The study failed to corroborate association between polymorphism CYP3A5∗3 and C3435T polymorphism in MDR1 gene and pharmacoresistant epilepsy and do not confirm the prognostic value of the polymorphisms examined in the prognostication of drug resistance in epilepsies.
Pharmacogenetics of oral anticoagulant therapy.
- BiologyCurrent pharmaceutical design
- 2010
The observational studies from the last decade provided valuable insights into the effects of genetic factors on variability in coumarin response and randomized clinical trials are needed to evaluate whether this genetic information will improve the benefit-risk ratio of coumarins.
References
SHOWING 1-10 OF 64 REFERENCES
Clinical Consequences of Cytochrome P450 2C9 Polymorphisms
- Biology, MedicineClinical pharmacology and therapeutics
- 2005
Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy.
- Medicine, BiologyPharmacogenomics
- 2006
In order for AED treatment guidelines to begin to have clinical impact, standards specific to the conduct of future AED studies must be established and the need for accurate epilepsy classification, appropriate AED selection and clear and objective assessment outcome measures must be understood.
Clinically relevant drug interactions with antiepileptic drugs.
- Medicine, BiologyBritish journal of clinical pharmacology
- 2006
Some patients with difficult-to-treat epilepsy benefit from combination therapy with two or more antiepileptic drugs (AEDs), and pharmacodynamic interactions involving AEDs have not been well characterized, but their understanding is important for a more rational approach to combination therapy.
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.
- Biology, MedicineProceedings of the National Academy of Sciences of the United States of America
- 2005
Evidence is provided of a drug target polymorphism associated with the clinical use of AEDs and set the stage for a prospective evaluation of how pharmacogenetic diagnostics can be used to improve dosing decisions in the use of phenytoin and carbamazepine.
IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?
- MedicineDrug Metabolism and Disposition
- 2005
It was determined that CYP2C9 plays a relatively minor role in the overall clearance of sulindac, naproxen, ketoprofen, diclofenac, rofecoxib, and etoricoxib and CYP1C9 genotype would have no clinically meaningful impact on the pharmacokinetics of these drugs.
CYP2C19 polymorphism effect on phenobarbitone
- Medicine, BiologyEuropean Journal of Clinical Pharmacology
- 2000
It appears that the disposition of PB is mediated in part by this enzyme, and the estimated population clearance values in the three genotype groups can be used to predict the PB dose required to achieve an appropriate serum concentration in an individual patient.
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.
- Biology, MedicineTrends in pharmacological sciences
- 2004
Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs
- Medicine, ChemistryTherapeutic drug monitoring
- 2003
Although routine monitoring of the newer antiepileptic drugs cannot be recommended at present, measurements of some of the drugs is undoubtedly of help with individualization of treatment in selected cases in a particular clinical setting.
Dosage Recommendation of Phenytoin for Patients with Epilepsy with Different CYP2C9/CYP2C19 Polymorphisms
- Medicine, BiologyTherapeutic drug monitoring
- 2004
The results revealed that the CYP 2C9 and CYP2C19 polymorphisms have dramatic effects on the population pharmacokinetic parameters of phenytoin, especially for CYP1C9.
The potential of pharmacogenetics in the treatment of epilepsy.
- Medicine, PsychologyEuropean journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
- 2006